Skip CCR Main Navigation National Cancer Institute National Cancer Institute U.S. National Institutes of Health
CCR - For Our Staff| Home |

Our Science – Kebebew Website

Electron Kebebew, M.D., F.A.C.S

Selected Publications

1)  Zhang L, Gaskins K, Yu Z, Xiong Y, Merino MJ, Kebebew E.
An in vivo mouse model of metastatic human thyroid cancer.
Thyroid. 24: 695-704, 2014.
2)  Weisbrod AB, Kitano M, Thomas F, Williams D, Gulati N, Gesuwan K, Liu Y, Venzon D, Turkbey I, Choyke P, Yao J, Libutti SK, Nilubol N, Linehan WM, Kebebew E.
Assessment of tumor growth in pancreatic neuroendocrine tumors in von Hippel Lindau syndrome.
J. Am. Coll. Surg. 218: 163-9, 2014.
3)  Lee P, Werner CD, Kebebew E, Celi FS.
Functional thermogenic beige adipogenesis is inducible in human neck fat.
Int J Obes (Lond). 38: 170-6, 2014.
4)  Ellis RJ, Wang Y, Stevenson HS, Boufraqech M, Patel D, Nilubol N, Davis S, Edelman DC, Merino MJ, He M, Zhang L, Meltzer PS, Kebebew E.
Genome-wide methylation patterns in papillary thyroid cancer are distinct based on histological subtype and tumor genotype.
J. Clin. Endocrinol. Metab. 99: E329-37, 2014.
5)  Desai SS, Modali SD, Parekh VI, Kebebew E, Agarwal SK.
GSK-3ß protein phosphorylates and stabilizes HLXB9 protein in insulinoma cells to form a targetable mechanism of controlling insulinoma cell proliferation.
J. Biol. Chem. 289: 5386-98, 2014.
6)  Lee P, Linderman JD, Smith S, Brychta RJ, Wang J, Idelson C, Perron RM, Werner CD, Phan GQ, Kammula US, Kebebew E, Pacak K, Chen KY, Celi FS.
Irisin and FGF21 are cold-induced endocrine activators of brown fat function in humans.
Cell Metab. 19: 302-9, 2014.
7)  Peng H, Talebzadeh-Farrooji M, Osborne MJ, Prokop JW, McDonald PC, Karar J, Hou Z, He M, Kebebew E, Orntoft T, Herlyn M, Caton AJ, Fredericks W, Malkowicz B, Paterno CS, Carolin AS, Speicher DW, Skordalakes E, Huang Q, Dedhar S, Borden KL, Rauscher FJ.
LIMD2 is a small LIM-only protein overexpressed in metastatic lesions that regulates cell motility and tumor progression by directly binding to and activating the integrin-linked kinase.
Cancer Res. 74: 1390-403, 2014.
8)  Nilubol N, Boufraqech M, Zhang L, Kebebew E.
Loss of CPSF2 expression is associated with increased thyroid cancer cellular invasion and cancer stem cell population, and more aggressive disease.
J. Clin. Endocrinol. Metab. jc20134140, 2014.
9)  Boufraqech M, Zhang L, Jain M, Patel D, Ellis R, Xiong Y, He M, Nilubol N, Merino M, Kebebew E.
miR-145 suppresses thyroid cancer growth and metastasis and targets AKT3.
Endocr. Relat. Cancer. [Epub ahead of print], 2014.
10)  Liu Y, Sadowski SM, Weisbrod AB, Kebebew E, Summers RM, Yao J.
Patient specific tumor growth prediction using multimodal images.
Med Image Anal. 18: 555-66, 2014.
11)  Sadowski SM, Weisbrod AB, Ellis R, Patel D, Alimchandani M, Quezado M, Millo C, Venzon DJ, Nilubol N, Linehan WM, Kebebew E.
Prospective Evaluation of the Clinical Utility of 18-Fluorodeoxyglucose PET CT Scanning in Patients with Von Hippel-Lindau-Associated Pancreatic Lesions.
J. Am. Coll. Surg. 218: 997-1003, 2014.
12)  Nella A, Lodish M, Fox E, Balis F, Quezado M, Whitcomb P, Derdak J, Kebebew E, Widemann B, Stratakis C.
Vandetanib successfully controls medullary thyroid cancer-related Cushing syndrome in an adolescent patient.
J. Clin. Endocrinol. Metab. jc20134340, 2014.
13)  Weisbrod AB, Webb RC, Mathur A, Barak S, Abraham SB, Nilubol N, Quezado M, Stratakis CA, Kebebew E.
Adrenal histologic findings show no difference in clinical presentation and outcome in primary hyperaldosteronism.
Ann. Surg. Oncol. 20: 753-8, 2013.
14)  Weisbrod AB, Zhang L, Jain M, Barak S, Quezado MM, Kebebew E.
Altered PTEN, ATRX, CHGA, CHGB, and TP53 Expression Are Associated with Aggressive VHL-Associated Pancreatic Neuroendocrine Tumors.
Horm Cancer. 4: 165-75, 2013.
15)  Weisbrod AB, Nilubol N, Weinstein LS, Simonds WF, Libutti SK, Jensen RT, Marx SJ, Kebebew E.
Association of type-O blood with neuroendocrine tumors in multiple endocrine neoplasia type 1.
J. Clin. Endocrinol. Metab. 98: E109-14, 2013.
16)  Liu-Chittenden Y, Kebebew E.
CpG island methylator phenotype in adrenocortical carcinoma: fact or fiction?.
J. Clin. Endocrinol. Metab. 98: 48-50, 2013.
17)  Boufraqech M, Patel D, Xiong Y, Kebebew E.
Diagnosis of thyroid cancer: state of art.
Expert Opin Med Diagn. 7: 331-42, 2013.
18)  Howard B, Wang Y, Xekouki P, Faucz FR, Jain M, Zhang L, Meltzer PG, Stratakis CA, Kebebew E.
Integrated Analysis of Genome-wide Methylation and Gene Expression Shows Epigenetic Regulation of CYP11B2 in Aldosteronomas.
J. Clin. Endocrinol. Metab. jc20133495, 2013.
19)  Patel D, Boufraqech M, Jain M, Zhang L, He M, Gesuwan K, Gulati N, Nilubol N, Fojo T, Kebebew E.
MiR-34a and miR-483-5p are candidate serum biomarkers for adrenocortical tumors.
Surgery. 154: 1224-8; discussion 1229, 2013.
20)  Liu Y, Sadowski SM, Weisbrod AB, Kebebew E, Summers RM, Yao J.
Multimodal image driven patient specific tumor growth modeling.
Med Image Comput Comput Assist Interv. 16: 283-90, 2013.
21)  Sadowski SM, He M, Gesuwan K, Gulati N, Celi F, Merino MJ, Nilubol N, Kebebew E.
Prospective screening in familial nonmedullary thyroid cancer.
Surgery. 154: 1194-8, 2013.
22)  Kim WG, Zhu X, Kim DW, Zhang L, Kebebew E, Cheng SY.
Reactivation of the silenced thyroid hormone receptor ß gene expression delays thyroid tumor progression.
Endocrinology. 154: 25-35, 2013.
23)  Ellis RJ, Patel D, Prodanov T, Sadowski S, Nilubol N, Adams K, Steinberg SM, Pacak K, Kebebew E.
Response after surgical resection of metastatic pheochromocytoma and paraganglioma: can postoperative biochemical remission be predicted?.
J. Am. Coll. Surg. 217: 489-96, 2013.
24)  Rahbari R, Kitano M, Zhang L, Bommareddi S, Kebebew E.
RTN4IP1 Is Down-Regulated in Thyroid Cancer and Has Tumor-Suppressive Function.
J. Clin. Endocrinol. Metab. 98: E446-54, 2013.
25)  Ellis RJ, Patel D, Prodanov T, Nilubol N, Pacak K, Kebebew E.
The Presence of SDHB Mutations Should Modify Surgical Indications for Carotid Body Paragangliomas.
Ann. Surg. [Epub ahead of print], 2013.
26)  Boufraqech M, Fassassi C, Kebebew E.
TLR-10 polymorphism and papillary thyroid cancer: one more SNP to consider?.
Endocrine. 43: 10-1, 2013.
27)  Jain M, Zhang L, He M, Zhang Y, Shen M, Kebebew E.
TOP2A is overexpressed and a therapeutic target for adrenocortical carcinoma.
Endocr. Relat. Cancer. 20: 361-70, 2013.
28)  Nilubol N, Weisbrod AB, Weinstein LS, Simonds WF, Jensen RT, Phan GQ, Hughes MS, Libutti SK, Marx S, Kebebew E.
Utility of intraoperative parathyroid hormone monitoring in patients with multiple endocrine neoplasia type 1-associated primary hyperparathyroidism undergoing initial parathyroidectomy.
World J Surg. 37: 1966-72, 2013.
29)  Sadowski SM, Kebebew E.
Variations on a theme. Variant venous adrenal anatomy at work.
JAMA Surg. 148: 384, 2013.
30)  Sadowski SM, Kebebew E.
Which hemostatic surgical devices should be used for thyroid surgery, or should we just continue to clamp and tie?.
Thyroid. 23: 1047-8, 2013.
31)  Smallridge RC, Ain KB, Asa SL, Bible KC, Brierley JD, Burman KD, Kebebew E, Lee NY, Nikiforov YE, Rosenthal MS, Shah MH, Shaha AR, Tuttle RM.
American Thyroid Association guidelines for management of patients with anaplastic thyroid cancer.
Thyroid. 22: 1104-39, 2012.
32)  Kebebew E.
Anaplastic thyroid cancer: rare, fatal, and neglected.
Surgery. 152: 1088-9, 2012.
33)  Weisbrod AB, Liewehr DJ, Steinberg SM, Patterson EE, Libutti SK, Marston Linehan W, Nilubol N, Kebebew E.
Association of type o blood with pancreatic neuroendocrine tumors in von hippel-lindau syndrome.
Ann. Surg. Oncol. 19: 2054-9, 2012.
34)  Gramza A, Kebebew E.
Cancer: Thyroid cancer bone metastases and high morbidity rates.
Nat Rev Endocrinol. 8: 454-5, 2012.
35)  Weisbrod AB, Kitano M, Gesuwan K, Millo C, Herscovitch P, Nilubol N, Linehan WM, Kebebew E.
Clinical utility of functional imaging with 18F-FDOPA in Von Hippel-Lindau syndrome.
J Clin Endocrinol Metab. 97: E613-7, 2012.
36)  Rechache NS, Wang Y, Stevenson HS, Killian JK, Edelman DC, Merino M, Zhang L, Nilubol N, Stratakis CA, Meltzer PS, Kebebew E.
DNA Methylation Profiling Identifies Global Methylation Differences and Markers of Adrenocortical Tumors.
J Clin Endocrinol Metab. 97: E1004-13, 2012.
37)  Kitano M, Rahbari R, Patterson EE, Steinberg SM, Prasad NB, Wang Y, Zeiger MA, Kebebew E.
Evaluation of candidate diagnostic micrornas in thyroid fine-needle aspiration biopsy samples.
Thyroid. 22: 285-91, 2012.
38)  Nilubol N, Zhang L, Shen M, Zhang YQ, He M, Austin CP, Kebebew E.
Four clinically utilized drugs were identified and validated for treatment of adrenocortical cancer using quantitative high-throughput screening.
J Transl Med. 10: 198, 2012.
39)  Jain M, Zhang L, He M, Patterson EE, Nilubol N, Fojo AT, Joshi B, Puri R, Kebebew E.
Interleukin-13 receptor alpha2 is a novel therapeutic target for human adrenocortical carcinoma.
Cancer. 118: 5698-708, 2012.
40)  Xekouki P, Hatch MM, Lin L, Rodrigo DA, Azevedo M, de la Luz Sierra M, Levy I, Saloustros E, Moraitis A, Horvath A, Kebebew E, Hoffman DA, Stratakis CA.
KCNJ5 mutations in the National Institutes of Health cohort of patients with primary hyperaldosteronism: an infrequent genetic cause of Conn's syndrome.
Endocr Relat Cancer. 19: 255-260, 2012.
41)  Jain M, Rechache N, Kebebew E.
Molecular markers of adrenocortical tumors.
J Surg Oncol. 106: 549-56, 2012.
42)  Nilubol N, Zhang L, Kebebew E.
Multivariate Analysis of the Relationship between Male Gender, Disease Specific Survival and Features of Tumor Aggressiveness in Thyroid Cancer of Follicular Cell Origin.
Thyroid. 23: 695-702, 2012.
43)  Hodin R, Angelos P, Carty S, Chen H, Clark O, Doherty G, Duh QY, Evans DB, Heller K, Inabnet W, Kebebew E, Pasieka J, Perrier N, Sturgeon C.
No need to abandon unilateral parathyroid surgery.
J. Am. Coll. Surg. 215: 297; author reply 297-300, 2012.
44)  Nilubol N, Weinstein L, Simonds WF, Jensen RT, Phan GQ, Hughes MS, Libutti SK, Marx S, Kebebew E.
Preoperative Localizing Studies for Initial Parathyroidectomy in MEN1 Syndrome: Is There Any Benefit?.
World J Surg. 36: 1368-74, 2012.
45)  Patel D, Kebebew E.
Pros and cons of robotic transaxillary thyroidectomy.
Thyroid. 22: 984-5, 2012.
46)  Zhang L, He M, Zhang Y, Nilubol N, Shen M, Kebebew E.
Quantitative high-throughput drug screening identifies novel classes of drugs with anticancer activity in thyroid cancer cells: opportunities for repurposing.
J. Clin. Endocrinol. Metab. 97: E319-28, 2012.
47)  Inchauste SM, Lanier BJ, Libutti SK, Phan GQ, Nilubol N, Steinberg SM, Kebebew E, Hughes MS.
Rate of clinically significant postoperative pancreatic fistula in pancreatic neuroendocrine tumors.
World J Surg. 36: 1517-26, 2012.
48)  Kebebew E.
Robotic posterior retroperitoneal adrenalectomy: for what benefit and at what cost?: Comment on.
Arch Surg. 147: 275-6, 2012.
49)  Yavuz S, Simonds WF, Weinstein LS, Collins MT, Kebebew E, Nilubol N, Phan GQ, Libutti SK, Remaley AT, Van Deventer M, Marx SJ.
Sleeping parathyroid tumor: rapid hyperfunction after removal of the dominant tumor.
J. Clin. Endocrinol. Metab. 97: 1834-41, 2012.
50)  Zhuang Z, Yang C, Lorenzo F, Merino M, Fojo T, Kebebew E, Popovic V, Stratakis CA, Prchal JT, Pacak K.
Somatic HIF2A gain-of-function mutations in paraganglioma with polycythemia.
N. Engl. J. Med. 367: 922-30, 2012.
51)  Patterson E, Webb R, Weisbrod A, Bian B, He M, Zhang L, Holloway AK, Krishna R, Nilubol N, Pacak K, Kebebew E.
The microRNA expression changes associated with malignancy and SDHB mutation in pheochromocytoma.
Endocr. Relat. Cancer. 19: 157-66, 2012.
52)  Turcotte S, Turkbey B, Barak S, Libutti SK, Alexander HR, Linehan WM, Hughes MS, Nilubol N, Gesuwan K, Millo C, Quezado M, Choyke PL, Kebebew E, Phan GQ.
von Hippel-Lindau disease-associated solid microcystic serous adenomas masquerading as pancreatic neuroendocrine neoplasms.
Surgery. 152: 1106-17, 2012.
53)  Webb R, Mathur A, Chang R, Baid S, Nilubol N, Libutti SK, Stratakis CA, Kebebew E.
What is the Best Criterion for the Interpretation of Adrenal Vein Sample Results in Patients with Primary Hyperaldosteronism?.
Ann. Surg. Oncol. 19: 1881-6, 2012.
54)  Wang CC, Friedman L, Kennedy GC, Wang H, Kebebew E, Steward DL, Zeiger MA, Westra WH, Wang Y, Khanafshar E, Fellegara G, Rosai J, Livolsi V, Lanman RB.
A large multicenter correlation study of thyroid nodule cytopathology and histopathology.
Thyroid. 21: 243-51, 2011.
55)  Gimm O, Castellone MD, Hoang-Vu C, Kebebew E.
Biomarkers in thyroid tumor research: new diagnostic tools and potential targets of molecular-based therapy.
J Thyroid Res. 2011: 631593, 2011.
56)  Zhang L, Rahbari R, He M, Kebebew E.
CDC23 regulates cancer cell phenotype and is overexpressed in papillary thyroid cancer.
Endocr. Relat. Cancer. 18: 731-42, 2011.
57)  Vriens MR, Moses W, Weng J, Peng M, Griffin A, Bleyer A, Pollock BH, Indelicato DJ, Hwang J, Kebebew E.
Clinical and molecular features of papillary thyroid cancer in adolescents and young adults.
Cancer. 117: 259-67, 2011.
58)  Kitano M, Millo C, Rahbari R, Herscovitch P, Gesuwan K, Webb RC, Venkatesan AM, Phan GQ, Hughes MS, Libutti SK, Nilubol N, Linehan WM, Kebebew E.
Comparison of 6-18F-fluoro-L-DOPA, 18F-2-deoxy-D-glucose, CT, and MRI in patients with pancreatic neuroendocrine neoplasms with von Hippel-Lindau disease.
Surgery. 150: 1122-8, 2011.
59)  Kitano M, Rahbari R, Patterson EE, Xiong Y, Prasad NB, Wang Y, Zeiger MA, Kebebew E.
Expression profiling of difficult-to-diagnose thyroid histologic subtypes shows distinct expression profiles and identify candidate diagnostic microRNAs.
Ann. Surg. Oncol. 18: 3443-52, 2011.
60)  Mathur A, Moses W, Rahbari R, Khanafshar E, Duh QY, Clark O, Kebebew E.
Higher rate of BRAF mutation in papillary thyroid cancer over time: a single-institution study.
Cancer. 117: 4390-5, 2011.
61)  Jain M, Zhang L, Patterson EE, Kebebew E.
KIAA0101 is overexpressed, and promotes growth and invasion in adrenal cancer.
PLoS ONE. 6: e26866, 2011.
62)  King KS, Prodanov T, Kantorovich V, Fojo T, Hewitt JK, Zacharin M, Wesley R, Lodish M, Raygada M, Gimenez-Roqueplo AP, McCormack S, Eisenhofer G, Milosevic D, Kebebew E, Stratakis CA, Pacak K.
Metastatic pheochromocytoma/paraganglioma related to primary tumor development in childhood or adolescence: significant link to SDHB mutations.
J. Clin. Oncol. 29: 4137-42, 2011.
63)  Vriens MR, Weng J, Suh I, Huynh N, Guerrero MA, Shen WT, Duh Q, Clark OH, Kebebew E.
MicroRNA expression profiling is a potential diagnostic tool for thyroid cancer.
Cancer. [Epub ahead of print], 2011.
64)  Patterson EE, Holloway AK, Weng J, Fojo T, Kebebew E.
MicroRNA profiling of adrenocortical tumors reveals miR-483 as a marker of malignancy.
Cancer. 117: 1630-9, 2011.
65)  Xiong Y, Zhang L, Holloway AK, Wu X, Su L, Kebebew E.
MiR-886-3p regulates cell proliferation and migration, and is dysregulated in familial non-medullary thyroid cancer.
PLoS ONE. 6: e24717, 2011.
66)  Nilubol N, Sukchotrat C, Zhang L, He M, Kebebew E.
Molecular pathways associated with mortality in papillary thyroid cancer.
Surgery. 150: 1023-31, 2011.
67)  Nilubol N, Kebebew E.
Personalizing thyroid cancer care: are we there yet?.
Ann. Surg. Oncol. 18: 1819-20, 2011.
68)  Moses W, Weng J, Kebebew E.
Prevalence, clinicopathologic features, and somatic genetic mutation profile in familial versus sporadic nonmedullary thyroid cancer.
Thyroid. 21: 367-71, 2011.
69)  Rahbari R, Mathur A, Kitano M, Guerrero M, Shen WT, Duh QY, Clark OH, Kebebew E.
Prospective randomized trial of ligasure versus harmonic hemostasis technique in thyroidectomy.
Ann. Surg. Oncol. 18: 1023-7, 2011.
Click Here to View Collapsed Bibliography.

This page was last updated on 5/2/2014.